Form 8-K - Current report:
SEC Accession No. 0001933414-25-000026
Filing Date
2025-03-31
Accepted
2025-03-31 08:15:36
Documents
14
Period of Report
2025-03-29
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mlys-20250329.htm   iXBRL 8-K 38351
2 EX-99.1 mlys202503318kex991.htm EX-99.1 30595
  Complete submission text file 0001933414-25-000026.txt   210603

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mlys-20250329.xsd EX-101.SCH 1794
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mlys-20250329_lab.xml EX-101.LAB 23449
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mlys-20250329_pre.xml EX-101.PRE 13589
16 EXTRACTED XBRL INSTANCE DOCUMENT mlys-20250329_htm.xml XML 2929
Mailing Address 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087
Business Address 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087 (888) 378-6240
Mineralys Therapeutics, Inc. (Filer) CIK: 0001933414 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41614 | Film No.: 25789024
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)